RET (V804E)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.V804E
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 2 | Selpercatinib | 99.7% | 0.3% | 96.72 |
| 3 | Entrectinib | 99.5% | 0.5% | 93.69 |
| 4 | Alpelisib | 99.4% | 0.6% | 97.22 |
| 5 | Tenalisib | 98.1% | 1.9% | 97.98 |
| 6 | Sunitinib | 96.1% | 3.9% | 91.73 |
| 7 | Brigatinib | 92.6% | 7.4% | 82.96 |
| 8 | Futibatinib | 91.7% | 8.3% | 98.48 |
| 9 | Defactinib | 89.8% | 10.3% | 92.68 |
| 10 | Repotrectinib | 89.4% | 10.6% | 84.21 |
| 11 | Fedratinib | 87.9% | 12.1% | 96.21 |
| 12 | Deucravacitinib | 87.6% | 12.4% | 98.99 |
| 13 | Tivozanib | 84.7% | 15.3% | 92.42 |
| 14 | Baricitinib | 84.7% | 15.3% | 97.99 |
| 15 | Ponatinib | 77.3% | 22.7% | 78.23 |
| 16 | Ruxolitinib | 73.7% | 26.3% | 98.25 |
| 17 | Avapritinib | 73.2% | 26.8% | 97.73 |
| 18 | Nintedanib | 69.9% | 30.1% | 90.23 |
| 19 | Capivasertib | 64.3% | 35.7% | 96.48 |
| 20 | Gilteritinib | 62.6% | 37.4% | 88.97 |
| 21 | Upadacitinib | 56.6% | 43.4% | 97.98 |
| 22 | Fostamatinib | 50.1% | 49.9% | 96.74 |
| 23 | Sorafenib | 47.4% | 52.6% | 96.72 |
| 24 | Abrocitinib | 44.3% | 55.7% | 99.50 |
| 25 | Pacritinib | 42.1% | 57.9% | 88.64 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 100.0% | 100.0% | +0.0% |
| Selpercatinib | 99.7% | 100.0% | -0.3% |
| Entrectinib | 99.5% | 99.6% | -0.1% |
| Alpelisib | 99.4% | 99.6% | -0.2% |
| Tenalisib | 98.1% | 98.5% | -0.4% |
| Sunitinib | 96.1% | 97.2% | -1.1% |
| Brigatinib | 92.6% | 94.9% | -2.2% |
| Futibatinib | 91.7% | 97.7% | -6.0% |
| Defactinib | 89.8% | — | — |
| Repotrectinib | 89.4% | — | — |
| Fedratinib | 87.9% | 99.9% | -12.0% |
| Deucravacitinib | 87.6% | — | — |
| Tivozanib | 84.7% | 99.7% | -15.0% |
| Baricitinib | 84.7% | — | — |
| Ponatinib | 77.3% | 100.0% | -22.7% |
| Ruxolitinib | 73.7% | — | — |
| Avapritinib | 73.2% | — | — |
| Nintedanib | 69.9% | 100.0% | -30.1% |
| Capivasertib | 64.3% | — | — |
| Gilteritinib | 62.6% | 100.0% | -37.4% |
| Upadacitinib | 56.6% | — | — |
| Fostamatinib | 50.1% | — | — |
| Sorafenib | 47.4% | 94.0% | -46.5% |
| Abrocitinib | 44.3% | — | — |
| Pacritinib | 42.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms